Retina

According to researchers, lesions in women’s eyes were significantly more likely to occur in the central retina compared with those in men’s eyes.

Intelligent Retinal Imaging Systems (IRIS) celebrates the company’s 1 millionth diabetic retinal exam.

According to the company, the Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with USH, with interim efficacy data anticipated by the end of the year.

According to company officials,the new image modality provides additional retinal visualization to our customers as they manage their patient’s treatment and ongoing care.

In a Wilmer Eye Institute study, in mice and human cell models, the drug 32-134D lowered protein levels known to contribute to diabetic macular edema and diabetic retinopathy

The research conducted at the Wayne State University School of Medicine implies that VCAM1 antagonism could be a promising therapeutic strategy for proliferative retinal disorders.

According to the company, topical administration is capable of delivering metformin to choroid, RPE, and retina.

Macular hole closure results from this novel treatment.

Early clinical studies indicate that Vitargus® has unique properties that could eliminate the need for patients to remain face-down after retinal detachment and vitreous hemorrhage surgery.

Study: AO retinal imaging has the potential to become a sensitive marker for disease.

A modified illuminated endolaser could be an efficient substitute for cryotherapy or indirect laser retinopexy during primary scleral buckling.

If approved, RVO would be the third indication for Vabysmo in addition to wet age-related macular degeneration and diabetic macular edema.

A team of researchers has now developed an approach to gather and compile a great deal of information about organoids and their development. The team applied its approach to the organoids of the human retina, which they derived from stem cells.

With the newly modified lighted endolaser probe, an 18-gauge angiocatheter sleeve protects against vitreous disturbance.

Inherited Retinal Diseases (IRD are genetic disorders that can cause severe vision loss or even blindness.

According to researchers, these chronic, progressive retinal diseases, including retinitis pigmentosa, arise from genetic and environmental disruptions of cellular and tissue stability.

Scientists at Medical College of Georgia demonstrated in their animal model of retinopathy of prematurity that the small molecule K604, which is being explored in cancer and Alzheimer’s, can block the development of leaky, obstructive blood vessels in the retina, tamp down inflammation and enable more normal blood vessel growth

RGC replacement represents a more formidable challenge.

Ram Kannan, PhD, FARVO, principal investigator and adjunct professor of Ophthalmology at David Geffen School of Medicine, UCLA, Doheny Eye Institute, made a pair of presentations at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans. He offers some of the highlights in a conversation with Ophthalmology Times.

Geographic atrophy is now a major research target.

According to the company, TSN-201 leverages AAV capsid that spreads laterally beyond subretinal injection site to facilitate safe delivery of RS1 to photoreceptors in the central retina/fovea.

The presentations highlighted the Clearside Biomedical’s efforts in suprachoroidal delivery of agents to the back of the eye.

The UCL-Moorfields team have developed a deep learning AI model to screen for ROP, which was trained on a sample of 7,414 images of the eyes of 1,370 newborns who had been admitted to the Homerton Hospital, London, and assessed for ROP by ophthalmologists.

In a presentation at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, Kiora Pharmaceuticals showed its investigational drug has the potential to restore light perception in patients who are blind or living with ultra-low vision due to retinitis pigmentosa.

Ophthalmology Times® talked with Michael Ip, MD, about the 5 year follow-up of the original SCORE2 dataset from the NIH-sponsored clinical trial.at this year's ARVO meeting.